New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
05:50 EDTTEVA, GRPNStocks with implied volatility movement; GRPN TEVA
Stocks with implied volatility movement; Groupon (GRPN) 68, Teva (TEVA) 33 according to iVolatility.
News For GRPN;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
09:10 EDTTEVAGevo announces Supreme Court rules in favor of Gevo
Gevo (GEVO) announced that the U.S. Supreme Court ruled in Gevo's favor and overturned an earlier Federal Circuit Court of Appeals ruling on the interpretation of key patent claims. The result is that Gevo's victory in the Delaware District Court is reinstated, and that the case has been remanded back to the Appeals Court for consideration in light of the new standard of appellate review that was decided in the Teva Pharmaceuticals USA, Inc., v. Sandoz, Inc. case last week. In Teva (TEVA), the Supreme Court ruled that the Appeals Court must apply a more stringent "clear error" standard of review, rather than a "de novo" standard of review. In Gevo's case, the Appeals Court must now apply the "clear error" standard of review and cannot set aside the Delaware District Court's findings of fact in Gevo's favor unless they were clearly erroneous. The Supreme Court's decision effectively reinstates Gevo's victory at the District Court where a final judgment of non-infringement was entered in Gevo's favor following the acknowledgment by Butamax Advanced Biofuels LLC that Gevo does not infringe Butamax's Patent Nos. 7,851,188 and 7,993,889.
January 26, 2015
15:24 EDTTEVATeva confirms U.S. approval of AstraZeneca's Nexium generic
Subscribe for More Information
14:15 EDTTEVATeva unit wins FDA approval for Nexium generic
Subscribe for More Information
January 23, 2015
16:08 EDTTEVATeva volatility elevated, Pfizer approached late last year, Bloomberg says
Teva (TEVA) overall option implied volatility of 25 compares to its 26-week average of 23 according to Track Data, suggesting large price movement into Pfizer (PFE) approach late last year, Bloomberg says.
16:04 EDTTEVATeva rebuffed Pfizer approach late last year, Bloomberg says
Subscribe for More Information
14:29 EDTGRPNGroupon volatility elevated
Groupon January weekly call option implied volatility is at 75, February is at 77, April is at 60; compared to its 26-week average of 53 according to Track Data, suggesting large February price movement into the expected release of Q4 results in February.
January 22, 2015
06:32 EDTGRPNBlue Calypso files motion to lift stay in patent infringement cases and appeal
Blue Calypso (BCYP) announced that it has filed a motion in the Eastern District of Texas to lift the negotiated stay on the pending patent infringement litigation between the Company and Groupon (GRPN), Yelp (YELP), Foursquare and IZEA.PK. The Company has also filed notices of appeal at the Federal Circuit Court of Appeals in each of the Covered Business Method Review cases at the Patent Trial and Appeals Board. On January 14, 2014, the parties agreed to stay the litigation in the Eastern District pending the decisions from the PTAB as to validity of the patents. As a part of agreeing to join the stay, the parties jointly agreed to ask the Court to lift the stay and for an expedited litigation schedule if any of the asserted claims were held valid by the PTAB. The PTAB now has confirmed the validity of twenty-eight claims and Blue Calypso, through its counsel, has asked the Court to lift the stay according to the agreement. The defendants refused to participate in the motion to lift the stay as previously agreed, and have instead asked the Court to leave the stay in place in a separate motion.
January 21, 2015
08:38 EDTTEVAMomenta announces Supreme Court decision to remand generic Copaxone back to CAFC
Subscribe for More Information
January 20, 2015
14:37 EDTTEVATeva generic competition to Copaxone pushed out by ruling, says BMO Capital
Subscribe for More Information
12:56 EDTTEVAMylan says continues to believe '808 patent is 'invalid'
Subscribe for More Information
11:29 EDTTEVATeva says Supreme Court reverses circuit court judgment on Copaxone 20 mg/mL
Teva Pharmaceutical announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for COPAXONE 20 mg/mL. The Supreme Court remanded the case to the Federal Circuit for further review in light of the applicable standard the Supreme Court laid out for appellate review of claim construction. A ruling last year by the U.S. Court of Appeals for the Federal Circuit upheld four Teva patents that expired in May 2014, while invalidating the ‘808 patent that is set to expire on September 1, 2015. “We are encouraged by the U.S. Supreme Court’s Decision and look forward to the Federal Circuit’s review. We will continue to explore all available avenues to protect our intellectual property for COPAXONE 20mg/mL,” said Erez Vigodman, President and CEO of Teva. “There is currently no FDA-approved follow-on version of Teva’s COPAXONE. We are encouraged by the FDA’s willingness to date to have dialogue regarding the complexities of COPAXONE 20 mg/mL and the potential limitations and other unknowns of purported follow-on versions,” added Rob Koremans, MD, President and CEO of Global Specialty Medicines at Teva.
10:45 EDTTEVATeva spikes, retraces, after win in Copaxone patent case
Subscribe for More Information
10:40 EDTTEVAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
10:35 EDTTEVATeva rises after patent ruling upheld by Supreme Court
The Supreme Court upheld a lower court ruling related to generic versions of Teva's Copaxone drug. In the ruling, the court wrote that "When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a “clear error,” not a de novo, standard of review." Teva shares are up 1.5% to $58.58 in early trading after the ruling. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use